Series AFrench biotech ErVimmune raises €17M to advance off-the-shelf cancer vaccine targeting HERVsThe French preclinical-stage biotech ErVimmune closed a €17 million series A round to bring its lead candidate cancer vaccine into the clinic. more ➔
AcquisitionGSK strengthens food allergy ambitions with $2.2bn RAPT Therapeutics acquisitionGSK has agreed to acquire California-based RAPT Therapeutics in a deal valued at $2.2 billion (€ 1.88 billion), expanding its respiratory, immunology and inflammation portfolio with a late-stage food … more ➔
Freepik.comFinancingHeidelberg-based Exciva secures €51M to tackle agitation in Alzheimer’s careAlzheimer’s disease means memory loss for those affected. Beyond this, however, it is above all relatives and care staff who are impacted when the loss of cognitive abilities is accompanied by symptoms … more ➔
IPOAgomAb files for U.S. IPO as fibrosis-focused pipeline moves deeper into the clinicAgomAb Therapeutics has filed for an initial public offering (IPO) in the U.S., looking to tap public markets to fund the next stage of development for its pipeline in fibrotic and inflammatory diseases. … more ➔
Clinical trialGenmab and AbbVie’s epcoritamab fails in phase 3 lymphoma studyLast week, Genmab and AbbVie hit a setback with epcoritamab, after the bispecific T-cell-engaging antibody failed to deliver a survival benefit in a phase 3 study in relapsed or refractory diffuse large … more ➔
Licence agreementGenethon licenses core AB-1009 technology to AskBio after IND clearanceFrench gene therapy research institute Genethon announced it has signed an exclusive global license with AskBio that allows the company to use Genethon-patented technology incorporated in AB-1009, an … more ➔
RegulatoryEMA and FDA join forces: Aligned principles on AI use in drug developmentThe European Medicines Agency (EMA) and the US Food and Drug Administration (FDA) have together compiled ten principles for good artificial intelligence (AI) practice in drug development. more ➔
FundingWith a €6.26M round, QLi5 doubles down on proteasome-based ADC payloadsQLi5 Therapeutics has completed a €6.26 million capital increase led by its Korean co-founder, Qurient, which has also increased its voting stake in the German biotech. The funding will be used to … more ➔
photo credit: BioInnovation Institute/Esben Zøllner OlesenInvestmentNovo Nordisk Foundation commits DKK 5.5 billion to scale European biotech innovationThe Novo Nordisk Foundation has committed up to DKK 5.5 billion (€736 million) to the BioInnovation Institute (BII), a Copenhagen-based hub for life science and deep tech entrepreneurship. The long-term … more ➔
CDC.govHerpes VirusMunich’s Innovative Molecules signs €125M partnership with Alfasigma to advance HSV encephalitis antiviralMunich-based Innovative Molecules steps into the spotlight with a partnership with Italy’s Alfasigma. The deal brings fresh capital and a global licence for adibelivir, a next-generation antiviral … more ➔
Freepik.com
photo credit: BioInnovation Institute/Esben Zøllner Olesen
CDC.gov